Amyloidosis, Hereditary Clinical Trial
Official title:
A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
The purpose of this study was to evaluate the safety and efficacy of revusiran (ALN-TTRSC) in patients with transthyretin (TTR) mediated Familial Amyloidotic Cardiomyopathy. Dosing has been discontinued; patients are being followed-up for safety.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05974644 -
Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry
|
||
| Recruiting |
NCT05879874 -
Prospective Evaluation of NfL as a Biomarker in ATTRv
|
||
| Recruiting |
NCT05489549 -
Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
|
||
| Completed |
NCT01960348 -
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
|
Phase 3 | |
| Active, not recruiting |
NCT03759379 -
HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
|
Phase 3 | |
| Recruiting |
NCT05873868 -
Myocardial Effects in Patients With ATTRv With Polyneuropathy Treated With Patisiran or Vutrisiran
|
||
| Approved for marketing |
NCT02939820 -
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
|
||
| Approved for marketing |
NCT03400098 -
ATTR Expanded Access Program (EAP) by Ionis
|